期刊文献+

临床标本中非发酵菌的分布及耐药性分析 被引量:3

Nonfermenter Distribution and Drug-resistance Analysis in Clinical Specimens
在线阅读 下载PDF
导出
摘要 目的了解临床标本中非发酵菌的分布及耐药状况,为合理使用抗菌药物提供依据。方法各种标本经分离培养,用ATB Expression细菌鉴定仪鉴定,用ATB PSE药敏试条进行药敏试验,并作统计分析。结果7 395份标本分离出非发酵1 106株,分离率为14.9%,以铜绿假单胞菌的分离率最高(45.7%),各种临床标本中以痰液标本的检出率最高;除嗜麦芽寡养单胞菌和脑膜脓毒金黄杆菌外,对亚胺培南的耐药率最低,其次为头孢哌酮/舒巴坦。结论非发酵菌在各种临床标本中分布不同,种类较多,各种细菌之间耐药性差异较大,临床应及时采集标本,作病原学检测及药敏试验,并根据药敏试验结果选择抗菌药物,以减少细菌耐药产生,控制医院感染。 OBJECTIVE To investigate the nonfermenter distribution and drug-resistance in the clinical specimens, and instruct clinical application of antibiotics reasonably. METHODS Bacteria were cultured, isolated and identified with ATB Expression microbe identification system. Drug-resistance was detected with ATB PSE and statistically analyzed. RESULTS A total of 1 106 strains of bacteria were isolated from 7 395 specimens, the isolation rate was 14. 9%. The isolation rate of Pseudomonas aeruginosa was the highest. The isolation rate of nonfermenter was the highest from sputum specimens. Nonfermenter was the most sensitive to imipenem except for Stenotrophomonas maltophilia and Chryseobacterium meningosepticum, after imipenem was cefoperazone/sulbactam. CONCLUSIONS The nonfermenter isolated from different clinical specimens and its drug-resistance are variant. To reduce the production of drug-resistance and control the nosocomical infection, the specimens must be collected and detected timely, the antibiotics are selected according to the results of susceptibility test.
作者 沈建人
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2006年第12期1422-1423,共2页 Chinese Journal of Nosocomiology
关键词 临床标本 非发酵菌 耐药性 Clinical specimens Nonfermenter Drug-resistance
  • 相关文献

参考文献5

二级参考文献30

  • 1瞿介明,胡必杰.老年人下呼吸道革兰阴性杆菌感染60例分析[J].中华老年医学杂志,1993,12(2):82-85. 被引量:11
  • 2[1]Jacoby GA,Mederiros AA. More extended-spectrum β-lactamases[J]. Antimicrob Agents Chemother,1991, 35(9):1697-1704.
  • 3[4]Sanders CC,Barry AL, Washington JA, et al. Detection of extended-spectrum β-lactamases-producing members of the family Enterobacteriaceae with the VITEK ESBLs test [J]. J Clin Microbiol, 1996,34(12): 2997-3001.
  • 4[5]Livermore DM. β-Lactamases in laboratory and clinical resistance [J]. J Clin Microbiol Rev, 1995, 8(3): 557-584.
  • 5[6]National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement [S]. NCCLS, 1999.19: 36-75.
  • 6[9]Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases [J]. Antimicrob Agents Chemother, 1997, 41(2): 223-232.
  • 7[10]Coudron PE, Molaand ES, Thomoson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center[J]. J Clin Microbiol, 2000, 38(5):1791-1796.
  • 8[11]Jacoby GA, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli [J]. J Clin Microbiol, 1996, 34(4): 908-911.
  • 9National committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement M100-S9 [ P ]. Wayne, Pennsglvania: National Committee for Clinical Laboratory Standards, 1999,19: 36-75.
  • 10Thomson ES, Sanders CC, Moland ES. Use of Microdilution Pnaels with and without β-Lactamase Inhibitors as a phenotypic test for β-Lactamase production among Escherichiacoli, Klebsiella spp, Enterobacter spp, Citrobacter freundii, and Seratia marcesens [J]. Antimicrob Agents chemother, 1999,43(6): 1393-1400.

共引文献132

同被引文献16

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部